Natera (NASDAQ: NTRA) executive chairman sells $20.13 million in shares

What happened

Natera, Inc. (NASDAQ: NTRA) said Matthew Rabinowitz sold 50,000 shares on 10/15/2026 under a Rule 10b5-1 plan. The Form 4 says Rabinowitz is executive chairman and a director. It also says the shares sold came from 50,000 stock options exercised the same day at $10.41 each. The filing reports sale prices from $388.32 to $408.24 per share and total proceeds of about $20.13 million.

After the trade, Rabinowitz held 2,119,394 shares. The filing lists 20 sale lines, each with a weighted-average price. It also says the option shares were fully exercisable and expire on 06/08/2027.

Key numbers

Metric	Latest	Change	Source
Shares sold	50,000 shares		SEC Form 4
Sale price range	from $388.32 to $408.24 per share		SEC Form 4
Total sale value	about $20.13 million		SEC Form 4
Shares held after sale	2,119,394 shares		SEC Form 4
Option exercise price	$10.41 per share		SEC Form 4

Read more: Natera (NTRA) stock analysis and investment case

Why it matters

OptimistFi's case is that Natera's value depends on proving that clinical adoption and reimbursement can keep scaling while the company turns rapid test growth into durable cash generation. This filing is mixed for that case. Rabinowitz still holds 2,119,394 shares, so the trade does not look like an exit. But it does cut his stake by about 2.3% from the 2,169,394 shares held before the reported transactions.

The filing also shows the trade was tied to same-day option activity. Rabinowitz exercised 50,000 options at $10.41 per share and then sold the shares in the open market at prices from $388.32 to $408.24 per share. That sequence points to a liquidity event rather than a change in ownership control. The main caveat is that the sale was made under a preplanned Rule 10b5-1 arrangement, which makes routine liquidity management a plausible reading.

The filing gives the post-trade holding, the price range, and the total value. Investors can use those details to track whether the executive's stake stays aligned with the business. It also shows that the shares sold came from exercised options, not from a long-held common-stock position. That matters because the trade trims the stake but leaves a large one in place.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Natera's next quarterly report is the next scheduled test for the broader investment case. A stronger report would show adoption and reimbursement still scaling while cash generation improves. A weaker report would show faster growth without better cash generation. Until then, the filing mainly shows that Rabinowitz sold under a prearranged plan and still held 2,119,394 shares after the trade. The 06/08/2027 option expiration is the other dated marker in the filing.

More from OptimistFi

• NTRA stock: the Natera thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps